Positive Blood Culture Removal Time Significantly Decreases Processing Time
|
By LabMedica International staff writers Posted on 18 Feb 2015 |
Timely processing of blood cultures with positive results, including Gram staining and notification of clinicians, is a critical function of the clinical microbiology laboratory.
Although empiric administration of antibiotics is critical, targeted therapy based on actionable data from the clinical microbiology laboratory must be implemented as soon as the data are available as inadequate antimicrobial treatment of bloodstream infections is associated with significantly increased mortality and, in surviving patients, increased hospital length of stay.
Scientists at the Houston Methodist Hospital (TX, USA) performed a retrospective analysis of positive blood culture processing times. Data for specimens collected seven months before and seven months after an in-service meeting were retrieved and analyzed. In some instances, no organisms were seen on initial Gram stain after a positive alert. In those cases, the culture bottles were returned to the automated blood culture system BACTEC FX instrument (BD Diagnostics, Sparks, MD, USA) for further incubation. As the Epicenter software does not log the initial removal, the positive-to-removal (PR) time was erroneously prolonged, and these samples were excluded from the analysis.
Before the in-service meeting, the average PR time for 5,057 samples was 38 minutes. They discovered unexpectedly that only 51.8% (2,617 of 5,057) of the positive blood cultures were removed in less than 10 minutes. After the in-service meeting, for 5,293 samples, the average PR time improved to eight minutes, the aggregate time also improved, and 84.5% (4,470 of 5,293) of the positive blood cultures were removed in less than 10 minutes. These improvements reduced the time to telephone notification of the Gram stain results to a caregiver by 46.7% (from 105 minutes to 56 minutes).
The authors concluded improvement of sepsis outcomes and costs requires rapid generation of actionable data from the clinical microbiology laboratory. Vigilant monitoring of parameters such as the PR time and meticulous identification of barriers to rapid pathogen identification has the potential to continue to decrease pathogen reporting time, decrease health care costs, and decrease morbidity and mortality associated with bloodstream infections. The study was published in the February 2015 issue of the Archives of Pathology & Laboratory Medicine.
Related Links:
Houston Methodist Hospital
BD Diagnostics
Although empiric administration of antibiotics is critical, targeted therapy based on actionable data from the clinical microbiology laboratory must be implemented as soon as the data are available as inadequate antimicrobial treatment of bloodstream infections is associated with significantly increased mortality and, in surviving patients, increased hospital length of stay.
Scientists at the Houston Methodist Hospital (TX, USA) performed a retrospective analysis of positive blood culture processing times. Data for specimens collected seven months before and seven months after an in-service meeting were retrieved and analyzed. In some instances, no organisms were seen on initial Gram stain after a positive alert. In those cases, the culture bottles were returned to the automated blood culture system BACTEC FX instrument (BD Diagnostics, Sparks, MD, USA) for further incubation. As the Epicenter software does not log the initial removal, the positive-to-removal (PR) time was erroneously prolonged, and these samples were excluded from the analysis.
Before the in-service meeting, the average PR time for 5,057 samples was 38 minutes. They discovered unexpectedly that only 51.8% (2,617 of 5,057) of the positive blood cultures were removed in less than 10 minutes. After the in-service meeting, for 5,293 samples, the average PR time improved to eight minutes, the aggregate time also improved, and 84.5% (4,470 of 5,293) of the positive blood cultures were removed in less than 10 minutes. These improvements reduced the time to telephone notification of the Gram stain results to a caregiver by 46.7% (from 105 minutes to 56 minutes).
The authors concluded improvement of sepsis outcomes and costs requires rapid generation of actionable data from the clinical microbiology laboratory. Vigilant monitoring of parameters such as the PR time and meticulous identification of barriers to rapid pathogen identification has the potential to continue to decrease pathogen reporting time, decrease health care costs, and decrease morbidity and mortality associated with bloodstream infections. The study was published in the February 2015 issue of the Archives of Pathology & Laboratory Medicine.
Related Links:
Houston Methodist Hospital
BD Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Channels
Clinical Chemistry
view channel
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
Oral squamous cell carcinoma can be difficult to triage at the point of care, resulting in frequent biopsies of lesions that ultimately prove benign. Limited access to pathology services in many communities... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more








